TrialSignal
Clinical trial intelligence report
A Phase I/IIa (Multi-center, Open-label, Phase I and Multi-center, Open-label, Phase IIa ) Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05188469-Jul 28, 2026
NCT ID
NCT05188469
Status
COMPLETED
Phase
Phase 1/2
Sponsor
EyeGene Inc.
Executive brief
Investment-Ready Snapshot
EyeGene Inc.'s EG-COVID and EG-COVARo vaccines are positioned within the competitive landscape of COVID-19 vaccine development, focusing on safety, tolerability, and immunogenicity in healthy adults. Given the ongoing global demand for effective COVID-19 vaccines, particularly with emerging variants, successful outcomes could enhance EyeGene's market presence and potential partnerships. The study's completion in early 2025 may align with ongoing vaccination campaigns, providing a strategic entry point into the market. However, the competitive landscape remains robust, with established players and new entrants continually innovating, necessitating vigilance in market positioning and differentiation strategies.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05188469
Indication
COVID-19 Vaccine
Modality
RNA therapy
Target
SARS-CoV-2 spike protein (mRNA-based vaccines targeting COVID-19)
Intervention
EG-COVID-003, EG-COVID-001, A: EG-COVID, B: EG-COVID, C: EG-COVARo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.